Table 2.
Uni‐ and multi‐variable linear regression analyses for association with the desmoplastic HGP.
| Original cohort – Erasmus MC Cancer Institute | ||||
|---|---|---|---|---|
| Univariable | Multivariable (n = 725) | |||
| β (95% CI) | P value | β (95% CI) | P value | |
| Primary tumour location, right‐ versus left‐sided or rectal | 1.26 (−5.92–8.44) | 0.731 | 0.74 (−6.59–8.06) | 0.843 |
| Primary tumour T‐stage, (y)pT 0–4* | −2.65 (−6.45–1.14) | 0.170 | −1.05 (−5.12–3.01) | 0.611 |
| Primary tumour nodal status, (y)pN 0–2* | −5.51 (−9.15–−1.87) | 0.003 | −5.49 (−9.42–−1.56) | 0.006 |
| Disease‐free interval, months* | −0.24 (−0.40–−0.09) | 0.002 | −0.04 (−0.21–0.14) | 0.664 |
| Number of CRLM* | 1.33 (0.28–2.38) | 0.013 | −0.15 (−1.38–1.07) | 0.806 |
| Diameter of largest CRLM, cm* | −2.48 (−3.54–−1.41) | <0.001 | −1.23 (−2.37–−0.09) | 0.035 |
| Preoperative CEA level, 100 μg/l* | −0.24 (−1.10–0.61) | 0.577 | −0.75 (−1.60–0.11) | 0.087 |
| Preoperative chemotherapy, yes versus no | 23.30 (18.18–28.42) | <0.001 | 24.57 (18.28–30.87) | <0.001 |
| External validation cohort – MSKCC | ||||
|---|---|---|---|---|
| Univariable | Multivariable (n = 899) | |||
| β (95% CI) | P value | β (95% CI) | P value | |
| Primary tumour location, right‐ versus left‐sided or rectal | −1.51 (−6.46–3.45) | 0.550 | 2.67 (−2.68–8.03) | 0.328 |
| Primary tumour T‐stage, (y)pT 0–4* | −1.36 (−4.75–2.04) | 0.433 | −2.21 (−5.95–1.54) | 0.247 |
| Primary tumour nodal status, (y)pN 0–2* | −2.48 (−5.42–0.45) | 0.097 | −6.19 (−9.50–−2.87) | <0.001 |
| Disease‐free interval, months* | −0.27 (−0.39–−0.15) | <0.001 | −0.12 (−0.28–0.04) | 0.149 |
| Number of CRLM* | 1.12 (0.20–2.04) | 0.017 | 0.02 (−1.08–1.12) | 0.977 |
| Diameter of largest CRLM, cm* | −2.11 (−2.87–−1.35) | <0.001 | −1.53 (−2.38–−0.68) | <0.001 |
| Preoperative CEA level, 100 μg/l* | −0.08 (−0.35–0.19) | 0.556 | −0.09 (−0.35–0.18) | 0.511 |
| Preoperative chemotherapy, yes versus no | 22.19 (17.69–26.69) | <0.001 | 24.18 (18.70–29.66) | <0.001 |
| Randomised patient cohort – EORTC 40983 trial | ||||
|---|---|---|---|---|
| Univariable | Multivariable (n = 68) | |||
| β (95% CI) | P value | β (95% CI) | P value | |
| Primary tumour location, right‐ versus left‐sided or rectal | 3.85 (−19.91–27.62) | 0.747 | 3.56 (−21.14–28.26) | 0.774 |
| Primary tumour T‐stage, (y)pT 0–4* | −4.69 (−23.85–14.47) | 0.627 | −0.86 (−21.15–19.43) | 0.933 |
| Primary tumour nodal status, (y)pN 0–2* | −4.84 (−19.05–9.37) | 0.499 | −5.71 (−20.83–9.42) | 0.453 |
| Disease‐free interval, months* | 0.15 (−0.48–0.77) | 0.645 | 0.09 (−0.56–0.73) | 0.785 |
| Number of CRLM* | 5.86 (−2.46–14.18) | 0.165 | 4.12 (−4.65–12.89) | 0.351 |
| Diameter of largest CRLM, cm* | −2.13 (−4.86–0.61) | 0.126 | −1.66 (−4.74–1.43) | 0.288 |
| Preoperative CEA level, 100 μg/l* | 0.03 (−0.05–0.11) | 0.425 | 0.02 (−0.06–0.11) | 0.597 |
| Treatment arm, CTx versus Rx arm | 27.97 (8.95–46.98) | 0.005 | 23.29 (1.78–44.79) | 0.034 |
CTx, chemotherapy; Rx, resection.
*
Entered as continuous variable.